Therapeutics for Hyponatremia and Polycystic Kidney Disease
AssigneeUniversity of Cincinnati
InventorHassane Amlal
Life of this patent
Estimating the term…
Abstract
A novel method for treating hyponatremia or polycystic kidney disease in a mammal is disclosed. The method involves administering to the mammal in need of such treatment a therapeutically effective amount of an adenine analog selected from the group consisting of: 2-chloro-6-aminopurine, its tautomer, racemate, optical isomer and/or pharmaceutically or nutritionally acceptable salt thereof, and a pharmaceutical carrier, 6-(dimethylamino) purine, its tautomer, racemate, optical isomer and/or pharmaceutically or nutritionally acceptable salt thereof, and a pharmaceutical carrier; and combinations thereof.
Claims14
A method for treating hyponatremia in a mammal, the method comprising administering to the mammal in need of such treatment a therapeutically effective amount of an adenine analog selected from the group consisting of:
- a. 2-chloro-6-aminopurine, its tautomer, racemate, optical isomer and/or pharmaceutically or nutritionally acceptable salt thereof, and a pharmaceutical carrier;
- b. 6-(dimethylamino) purine, its tautomer, racemate, optical isomer and/or pharmaceutically or nutritionally acceptable salt thereof, and a pharmaceutical carrier;
- c. and combinations thereof.
A method for treating polycystic kidney disease in a mammal, the method comprising administering to the mammal in need of such treatment a therapeutically effective amount of an adenine analog selected from the group consisting of:
- a. 2-chloro-6-aminopurine, its tautomer, racemate, optical isomer and/or pharmaceutically or nutritionally acceptable salt thereof, and a pharmaceutical carrier;
- b. 6-(dimethylamino) purine, its tautomer, racemate, optical isomer and/or pharmaceutically or nutritionally acceptable salt thereof, and a pharmaceutical carrier;
- c. and combinations thereof.
Dependencies are inferred from the claim text.